Please assess the completion status of the following clinical trial:

Trial Title: Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* With signed consent~* Histologically confirmed invasive breast carcinoma with a primary tumor size of no less than (≥) 2 centimeters (cm) by standard local assessment technique~* Breast cancer stage at presentation: stage I-III~* HER2-positive breast cancer defined as 3+ score by immunohistochemistry in \> 10 percent (%) of immunoreactive cells or HER2 gene amplification by in situ hybridization~* Known hormone receptor status (estrogen receptor and/or progesterone receptor)~* Eastern Cooperative Oncology Group Performance Status equal to or less than (\<=) 1~* Baseline left ventricular ejection fracture \>= 50% measured by echocardiography~* Willing to use highly effective form of nonhormonal contraception while on study and for 7 months after end of study treatment for female with fertility or male~* Negative serum pregnancy test for women with fertility~* Willing to obey the study protocol~Exclusion Criteria:~* Stage IV disease~* Previous anti-cancer therapy or radiotherapy for any malignancy~* History of other malignancy within 5 years prior to screening, except for appropriately-treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, or Stage I uterine cancer~* Concurrent anti-cancer treatment in another investigational trial, including hormone therapy, bisphosphonate therapy, or immunotherapy~* Major surgical procedure unrelated to breast cancer within 4 weeks prior to randomization or from which the participant has not fully recovered~* Serious cardiac illness or medical condition~* Other concurrent serious diseases that may interfere with planned treatment, including severe pulmonary conditions/illness~* Any abnormalities in liver, kidney or hematologic function laboratory tests immediately prior to randomization~* Sensitivity to any of the study medications, any of the ingredients or excipients of these medications, or benzyl alcohol~* Not able to swallow the drug~* Pregnant or lactating

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Pyrotinib in combination with nab-paclitaxel (Type: EXPERIMENTAL): Prior to surgery: pyrotinib and nab-paclitaxel for 4 cycles (1 cycle = 21 days). After surgery/chemotherapy with epirubicin and cyclophosphamide (EC): trastuzumab up to 1 year total.
- Trastuzumab in combination with nab-paclitaxel (Type: ACTIVE_COMPARATOR): Prior to surgery: trastuzumab and nab-paclitaxel for 4 cycles (1 cycle = 21 days). After surgery/chemotherapy with epirubicin and cyclophosphamide (EC): trastuzumab up to 1 year total.

Based on this trial design, predict the completion outcome and termination type (if applicable).